

Astellas at ASCO 2021
Presentation Overview

Abstract Title	Lead Author	Session Timing	Type	Abstract Number
Enfortumab Vedotin				
Study EV-103: Update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC)	T. Friedlander	Poster available to view on demand June 4 at 9 a.m. ET	Poster	4528
Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors: An updated analysis of EV-201 Cohort 2	B. McGregor	Poster available to view on demand June 4 at 9 a.m. ET	Poster	4524
Quality of Life, Functioning, and Symptoms in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma From EV-301: A Randomized Phase 3 Trial of Enfortumab Vedotin versus Chemotherapy	R. Mamtani	Poster available to view on demand June 4 at 9 a.m. ET	Poster	4539
KEYNOTE-B15/EV-304: randomized phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC)	C. Hoimes	Poster available to view on demand June 4 at 9 a.m. ET	Poster	TPS4587
Opioid Use in Locally Advanced or Metastatic Urothelial Carcinoma Patients and Matched Non-Cancer Controls	S. Grewal	Publication Only	Abstract	e16517
Enzalutamide				
The efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) on bone oligometastatic hormone-sensitive prostate cancer: a post hoc analysis of ARCHES	A. Armstrong	Poster available to view on demand June 4 at 9 a.m. ET	Poster	5071
Real world first-line treatment patterns in patients with metastatic castration-sensitive prostate cancer (mCSPC) in a U.S. health insurance database	U. Swami	Poster available to view on demand June 4 at 9 a.m. ET	Poster	5072
Real-world treatment patterns among patients diagnosed with metastatic castration-sensitive prostate cancer (mCSPC) in community oncology settings	D. George	Poster available to view on demand June 4 at 9 a.m. ET	Poster	5074
Real-world utilization of advanced therapies and racial disparity among patients with metastatic castration-sensitive prostate cancer (mCSPC): a Medicare database analysis	S. Freedland	Poster available to view on demand June 4 at 9 a.m. ET	Poster	5073
Gilteritinib				
Follow-up of Patients With FLT3-Mutated R/R AML in the Phase 3 ADMIRAL Trial	A. Perl	Poster available to view on demand June 4 at 9 a.m. ET	Poster	7013
Zolbetuximab				
Effect of ethnicity and chemotherapy (mFOLFOX6) on zolbetuximab pharmacokinetics in patients with claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)	S. Klempner	Publication Only	Abstract	e16078
Phase 2 study of zolbetuximab plus mFOLFOX6 in claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ): ILUSTRO cohort 2	K. Lee	Publication Only	Abstract	e16063

###